USAID: African HIV Vaccine Trial Halted Weeks Before Launch

The BRILLIANT Consortium, an African-led, multidisciplinary HIV vaccine research partnership funded by USAID and led by the South African Medical Research Council, saw its grant terminated in early 2025. Launched in 2023 as a five-year effort, the first-of-its-kind project was structured to shift the nexus of HIV vaccine development leadership to African scientists by building durable clinical research and manufacturing capacity in countries most affected by HIV.

When the stop-work order was issued in January 2025, BRILLIANT was weeks away from launching a complex, multi-country Phase 1 HIV vaccine trial testing two promising vaccines derived from African viral strains. Vaccines had already been manufactured, regulatory approvals secured, sites trained, and extensive community engagement completed across several countries, when all efforts ceased. The council secured limited philanthropic and South African government funding to launch a scaled-down version the trial in South Africa in early 2026, but at significant costs. The trial was delayed by nearly a year and reduced to a single arm; planned sites in other African countries were cancelled, and key comparisons on different dosing and immune priming strategies were dropped. As a results, years of preparatory investments across multiple countries will now produce only a faction of the intended evidence.

The program was also preparing to begin manufacturing the next phase of vaccine components for new candidates, with a long-term goal of shifting manufacturing know-how from a partner in India to an African manufacturer. That effort was also halted, with no clear path forward. The termination led to layoffs among specialized scientific and community engagement staff and dismantled trial teams outside South Africa. US-based collaborators, including Duke University, Harvard University, and Fred Hutchinson Cancer Center, who were involved in vaccine design and manufacturing, also lost a major scientific partnership and pipeline opportunity for their research. Overall, the termination reduced scientific ambition and insights on a trial, wasted prior investments in trial readiness, and weakened a transnational research ecosystem intended to support HIV vaccine development for the benefit of both US and global public health.